Karma Biotechnologies is an innovative oncology company focused on developing advanced treatments for solid tumors, with a particular emphasis on colorectal cancer. The company operates in the biotechnology and pharmaceutical market, aiming to revolutionize cancer treatment through its proprietary localized IL-15 technology. This technology is designed to convert 'cold' tumors, which are resistant to the immune system, into 'hot' tumors that can be effectively targeted and eliminated by the body's natural defenses.

Karma Biotech serves a diverse range of clients, including healthcare providers, research institutions, and pharmaceutical companies. The business model is centered around research and development, clinical trials, and eventual commercialization of its therapies. Revenue is generated through partnerships, licensing agreements, and sales of its proprietary treatments once they receive regulatory approval.

The company is led by a team of experienced professionals, including Joe Turner, CFO and CBO, who brings extensive financial and strategic expertise from his previous roles at Blackstone and PJT. Xazmin Custer, PhD, serves as the Director of Molecular Biology, leveraging her expertise in metabolism and cell signaling to drive the company's research initiatives.

Keywords: oncology, solid tumors, colorectal cancer, IL-15 technology, immune response, biotechnology, pharmaceutical, clinical trials, commercialization, cancer treatment.